Venous thromboembolism (VTE) and glioblastoma

Journal of Neuro-Oncology

Volumn 124, Issue 1, 2015, Pages 87-94

  Yust Katz, Shlomit ^a,b   Mandel, Jacob J ^c   Wu, Jimin ^e   Yuan, Ying ^e   Webre, Courtney ^d   Pawar, Tushar A ^e   Lhadha, Harshad S ^e   Gilbert, Mark R ^e   Armstrong, Terri S ^e,f  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEXAS A M COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

Brain tumors; Deep vein thrombosis; Pulmonary emboli

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; STEROID; TEMOZOLOMIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CEREBRAL SINUS THROMBOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DRUG USE; FEMALE; GLIOBLASTOMA; HUMAN; KHORANA SCALE; LEUKOCYTE COUNT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTIVE VALUE; RATING SCALE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; VENOUS THROMBOEMBOLISM; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; BRAIN NEOPLASMS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84937526459     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1805-2     Document Type: Article

References (29)

1. Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using medicare claims data. Medicine (Baltimore) 78:285–291
2. Anderson F, Huang W, Sullivan C, et al (2001) The continuing risk of venous thromboembolism following operation for glioma: findings from the Glioma Outcomes Project. Thromb Hemost, 86(Suppl):OC902
3. Brandes AA, Scelzi E, Salmistraro G et al (1997) Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33:1592–1596
4. Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence based review. Cancer 89:640–646
5. Perry JR (2012) Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 14(Suppl 4):iv73–iv80
6. Chaichana KL, Pendleton C, Jackson C, Quinones-Hinojosa A (2013) Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurol Res 35(2):206–211
7. Khorana AA (2012) Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res 129(Suppl 1):S10–S15. doi:10.1016/S0049-3848(12)70009-9
8. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27(29):4839–4847
9. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907. doi:10.1182/blood-2007-10-116327Epub 2008 Jan 23
10. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481
11. Huerta C, Johansson S, Wallander MA, Garcı´a Rodrı´guez LA (2007) Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167(9):935–943
12. Johannesdottir SA, Horváth-Puhó E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolisma nationwide population-based case-control study. JAMA Intern Med 173(9):743–752
13. Squizzato A, Gerdes VE, Ageno W, Bu¨ller HR (2007) The coagulation system in endocrine disorders: a narrative review. Intern Emerg Med 2(2):76–83
14. van Zaane B, Nur E, Squizzato A et al (2010) Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost 8(11):2483–2493
15. Thaler J, Ay C, Kaider A, et al. (2014) Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol, nou106 (PubMed PMID: 24987133)
16. Thaler J, Preusser M, Ay C, Kaider A et al (2013) Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 131(2):162–165
17. Jenkins EO, Schiff D, Mackman N, Key NS (2010) Venous thromboembolism in malignant gliomas. J Thromb Hemost 8:221–227
18. Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA (2002) Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost 88:213–220
19. Paredes N, Xu L, Berry LR, Chan AK (2003) The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol 120:315–324
20. Walsh J, Wheeler HR, Geczy CL (1992) Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 81:480–488
21. Rogers JS II, Murgo AJ, Fontana JA, Raich PC (1988) Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6:276–281
22. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC (2006) Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther 5:3303–3311
23. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L (1996) The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 7:731–737
24. Kuenen BC, Levi M, Meijers JC et al (2002) Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 22:1500–1505
25. Thaler J, Ay C, Kaider A, Reitter EM, Haselböck J, Mannhalter C, Zielinski C, Marosi C, Pabinger I (2014) Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol, nou106
26. Perry JR, Julian JA, Laperriere NJ et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8(9):1959–1965
27. Robins HI, O’Neill A, Gilbert M et al (2008) Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 62:227–233
28. Perry SL, Bohlin C, Reardon DA et al (2009) Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 95:129–134
29. Salmaggi A, Simonetti G, Trevisan E, Beecher D, Carapella CM, DiMeco F, Conti L, Pace A, Filippini G (2013) Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. J Neurooncol 113(2):293–303